Clotting - Venous thrombosis: Sex-specific differences in prevalence of pulmonary embolism among patients with venous thromboembolism (Luuk Scheres)
|
|
|
|
|
|
|
Clotting - Venous thrombosis: The risk of recurrent venous thrombosis in patients undergoing surgery after a first thrombotic event (Banne Nemeth)
|
|
|
|
|
|
|
Clotting - Venous thrombosis: Association of impaired renal function with venous thrombosis: a genetic risk score approach (Romain Charmet)
|
|
|
|
|
|
|
Clotting - Venous thrombosis: Repeated measures of carotid atherosclerosis and future risk of venous thrombosis (Birgit Småbrekke)
|
|
|
|
|
|
|
Clotting - Venous thrombosis: Protein C activity is associated to early formation of new Q waves and failure to achieve ST segment resolution in patients with acute ST segment elevation myocardial infarction (Slobodan Obradovic)
|
|
|
|
|
|
|
Clotting- Venous thrombosis: PDGFB, a new candidate plasma biomarker for venous thromboembolism (Maria Jesus Iglesias)
|
|
|
|
|
|
|
Clotting - Structure and function: Tissue factor expressed by different cell types regulates central nervous system haemostasis and autoimmune inflammation in a mouse model of multiple sclerosis (Rafal Pawlinski)
|
|
|
|
|
|
|
Clotting - Structure and function: The C-terminus of TFPIα inhibits factor V activation by protecting the Arg1545 cleavage site (Peter van Doorn)
|
|
|
|
|
|
|
Clotting - Structure and function: Factor V functions as a synergistic cofactor with protein S in the inhibition of FXa by TFPI (Salvatore Santamaria)
|
|
|
|
|
|
|
Clotting - Structure and function: New modulators of SERPINC1 gene expression. Relevance for antithrombin levels and potential therapeutic usefulness (Mara Toderici)
|
|
|
|
|
|
|
Clotting - Structure and function: Conformational activation of ADAMTS13: The spacer-CUB/VWF-D4CK domain interactions (Kieron South)
|
|
|
|
|
|
|
Bleeding - Experimental models: Complete loss of CalDAG-GEFI expression leads to severe bleedings caused by altered platelet function (Matthias Canault)
|
|
|
|
|
|
|
Bleeding - Experimental models: A fusion protein of interleukin-4 and interleukin-10 protects against blood-induced cartilage damage in vitro and in vivo (Lize van Vulpen)
|
|
|
|
|
|
|
Bleeding - Experimental models: Matrix metalloproteinase inhibition (CM352) effectively reduces rivaroxaban but not dabigatran associated experimental bleeding (Jose A. Paramo)
|
|
|
|
|
|
|
Bleeding - Experimental models: Efficient and allele-specific siRNAs that target von Willebrand factor single nucleotide polymorphisms as a potential personalized therapy for von Willebrand disease (Annika de Jong)
|
|
|
|
|
|
|
Bleeding - Experimental models: The correlation between biomarkers of joint cartilage degradation and markers of oxidative stress in patients with severe haemophilia treated by different prophylaxis regimens (Mirjana Mitrovic)
|
|
|
|
|
|
|
Bleeding - Experimental models: Depletion of prekallikrein improves host defense during Gram-negative pneumonia derived sepsis (Chao Ding)
|
|
|
|
|
|
|
Platelets - Mechanism and regulation: GPV is a central regulator of haemostasis, thrombosis and thrombo-inflammatory brain infarction in mice (Sarah Beck)
|
|
|
|
|
|
|
Platelets - Mechanism and regulation: Blocking heteromerization of platelet chemokines CCL5 and CXCL4 reduces inflammation and preserves heart function after myocardial infarction (Rory Koenen)
|
|
|
|
|
|
|
Platelets - Mechanism and regulation: platelet-derived S1P promotes recovery from anaphylactic shock but is redundant for vascular integrity (Eric Camerer)
|
|
|
|
|
|
|
Platelets - Mechanism and regulation: Defects in TRPM7 function result in abnormal Ca2+ dependent platelet signaling in mice (Sanjeev Gotru)
|
|
|
|
|
|
|
Platelets - Mechanism and regulation: Platelet-thrombi induce an unstable plaque phenotype and arterial stiffening locally at the site of vascular injury (Judith Cosemans)
|
|
|
|
|
|
|